Real-world Dosing Patterns of Rivaroxaban in the United States

Completed

Phase N/A Results N/A

Trial Description

The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.
The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).

Conditions

Interventions

  • Rivaroxaban (Xarelto, BAY59-7939) Drug
    Intervention Desc: As prescribed by treating physicians
    ARM 1: Kind: Experimental
    Label: NVAF patients receiving 20 mg rivaroxaban
    Description: NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
    ARM 2: Kind: Experimental
    Label: NVAF patients receiving 15 mg rivaroxaban
    Description: NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)

Trial Population

Patients with non-valvular atrial fibrillation (NVAF)

Outcomes

Type Measure Time Frame Safety Issue
Primary Number of NVAF patients receiving 20 mg Rivaroxaban At baseline
Primary Number of NVAF patients receiving 15 mg Rivaroxaban At baseline
Secondary Baseline renal function At baseline

Sponsors